Live Breaking News & Updates on Biosimilars

Stay informed with the latest breaking news from Biosimilars on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Biosimilars and stay connected to the pulse of your community

Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

Kostas-botsoglou , Sophia-humphreys , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Uptake-of-adalimumab , Strategies ,

Selecting Between Adalimumab Biosimilars for Your Patients

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

Kostas-botsoglou , Sophia-humphreys , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Treatment-selection ,

Dr Leslie Fish on Future Biosimilar Trends in Managed Care Pharmacy

Leslie Fish, PharmD, senior vice president of pharmacy at IDP Analytics, LLC, reflects on the future of biosimilars and the impact they will have on managed care pharmacy settings to improve patient access to medications.

Leslie-fish , Academy-of-managed-care-pharmacy , Traditional-pharmaceuticals-brands , Managed-care-pharmacy , Traditional-pharmaceuticals , Biosimilars , Managed-care , Pharmacy ,

An Overview of Health Care and Pharmaceutical Trends, 2023-2024

Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.

United-states , Fan-alert-network , National-sales-perspectives , Academy-of-managed-pharmacy , Health-services-utilization-index , Health-care-trends , Managed-pharmacy , Care-trends , Alert-network , Services-utilization-index , Sales-perspectives

How Providers Can Ease Patient Anxieties When Switching to Biosimilars: Adam Colborn

Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, discussed how providers can comfortably switch patients to biosimilars while minimizing anxieties, as well as the impacts prior authorization requirements can have on patient access.

Adam-colborn , Academy-of-managed-care-pharmacy , Managed-care-pharmacy , Boundaries-with-interchangeable-biosimilars , Biosimilars , Prior-authorization , Amcp ,

Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Adalimumab , Gastro , Rheumatoid-arthritis , Ra , Dermatology

The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

United-states , New-york , Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Pharmacy-benefit-managers , Payers , Adalimumab , Pbms

Infliximab and Biosimilar Yield Similar Results in IBD

New data supported the safety and efficacy of nonmedical switching from infliximab to a biosimilar, according to researchers.

Canada , United-kingdom , Vancouver , British-columbia , Canadian , British , Thomas-tam-hoang , Laura-targownik , University-of-toronto-temerty-faculty-medicine , Centre-of-british-columbia , Journal-of-the-canadian-association-gastroenterology , Health-canada

9 Biosimilars for Intravitreal nAMD, DME Treatment

A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.

South-korea , P-biocon-biologics , Aflibercept-eylea-biosimilars , Chong-kun-dang , Ranibizumab-lucentis-biosimilars , Samsung-bioepis , Momenta-pharmaceuticals , Biocon-biologics , Ophthalmology , Biosimilars , Biosimilar , Retina

The Pharmacological Aspects of Adalimumab Biosimilars

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Citrate-free ,

Live Breaking News & Updates on Biosimilars

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Adalimumab , Gastro , Rheumatoid-arthritis , Ra , Dermatology

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Citrate-free ,

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Adalimumab , Gastro , Rheumatoid-arthritis , Ra , Dermatology

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Citrate-free ,